Summary
Monoamine oxidase type B (MAO-B) and superoxide dismutase (SOD) are two enzyme stystems that are potentially relevant to an oxidative stress model of Parkinson's disease (PD) causation. Activities of MAO-B in platelets (nmol/108 cells/hr) and total SOD in lymphocytes (U/mg protein) were assayed among 28 cases of idiopathic PD and 22 controls. As anticipated, MAO-B was lowest in PD cases on selegiline (L-deprenyl) therapy (mean 1.10). There was a slight deficit of MAO-B among male cases not taking selegiline compared to controls (3.78 vs. 4.15), but the opposite trend was observed for females (6.18 vs. 4.16). SOD was slightly higher in cases (7.40), than controls (6.81). Excess SOD among PD cases was seen irrespective of gender, age, or selegiline treatment, although none of the differences was statistically significant Future research on SOD should take advantage of the availability of assays specific for the cytosolic and mitochondrial forms of the enzyme.
Similar content being viewed by others
References
Adams JD, Odunze IN (1991) Oxygen free radicals: their involvement in disease processes. Ann Clin Biochem 27: 161–169
Bonucelli U, Piccini P, Del Dotto P, Pacifici GM, Corsini GU, Muratorio A (1990) Platelet monoamine oxidase B activity in Parkinsonian patients. J Neurol Neurosurg Psychiatry 53: 854–855
Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Invest 21 [Suppl 97]: 77–89
Calne DB, Langston JW (1983) Aetiology of Parkinson's disease. Lancet ii: 1457–1459
Carillo M, Kanai S, Kitani K (1991) (-) Deprenyl induces activities of both superoxide dismutase and catalase but not glutathione peroxidase in the striatum of young rats. Life Sci 48: 517–521
Ceballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y (1990) Superoxide dismutase in Parkinson's disease. Lancet 335: 1035–1036
Checkoway H, Costa LG, Camp J, Coccini T, Daniell WE, Dills R (1992) Peripheral markers of neurochemical function among styrene-exposed workers. Br J Ind Med (in press)
Cohen G (1986) Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 119–125
Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G (1988) Platelet MAO-B activity and psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand 78: 730–736
Golbe LI, Farrell TM, Davis PH (1990) Follow-up study of early life protective and risk factors in Parkinson's disease. Mov Disord 5: 66–70
Hamet P, Fraysse T, Franks DL (1978) Cyclic nucleotides and aggregation of platelets of psontaneously hypertensive rats. Circ Res 43: 365–374
Hertzman C, Wiens M, Bowering D, Snow B, Calne D (1990) Parkinson's disease: a casecontrol study of occupational and environmental risk factors. Am J Ind Med 17: 349–355
Humfrey CDN, Steventon GB, Sturman SG, Waring RH, Griffiths B, Williams AC (1990) Monoamine oxidase substrates in Parkinson's disease. Biochem Pharmacol 40: 2562–2564
Johnson JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Irwin I, Langston EB, Forno LS (1984) 1-Methyl-4-phenylpyridinium on (MPP+): identification of metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48: 87–92
Lee DH, Mendoza M, Dvorozniak MT, Chung E, van Woert MH, Yahr MD (1989) Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. J Neural Transm [P-D Sect] 1: 189–194
Lunec J (1990) Free radicals: Their involvement in disease processes. Ann Clin Biochem 27: 173–182
Mann JJ, Stanley M, Kaplan RD, Sweeney J, Neophytides A (1983) Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease. J Neurol Neurosurg Psychiatry 46: 905–910
Maret G, Testa B, Jenner P, EI Tayar N, Carrupt P-A (1990) The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metab Rev 22: 291–332
Martilla RJ, Lorentz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson's disease: Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86: 321–331
McCord JM, Fridovitch I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049–6055
Murphy Dl, Wright C, Buschbaum M, Nichols A, Costa JL, Wyatt RJ (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16: 254–265
Nakano M, Kimura H, Hara M, Kuroiwa M, Kato M, Totsune K, Yoshikawa T (1990) A highly sensitive method for determining both Mn- and Cu−Zn superoxide dismutase activities in tissues and blood cells. Anal Biochem 187: 277–280
Ngim C-H, Devathasan G (1989) Epidemiologic study of the association between body 290 H. Checkoway et al.: MAO-B and superoxide dismutase in Parkinson's disease burden mercury level and idiopathic Parkinson's disease. Neuroepidemioly 8: 128–141
Ohno H, Yahara O, Ishikawa M, et al (1990) Serum manganese-superoxide dismutase in individuals with various neuromuscular diseases. Free Rad Biol Med 9: 137
Olanow CW (1990) Oxidative reactions in Parkinson's disease. Neurology 40 [Suppl 3]: 32–37
Riederer P, Konradi C, Youdim MBH (1990) The role of MAO in dopaminergic transmission. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Parkinson's disease: anatomy, pathology, and therapy, Raven Press, New York, pp 149–153 (Adv neurol 53)
Rosetti ZL, Sotgio A, Sharp DE, Hadjiconstantinou M, Neff NH (1988) 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol 37: 4573–4574
Saggu H, Cooksey J, Dexter D, Wells FR, Less A, Jenner P, Marsden CD (1989) A selective increase in particulate superoxide dismutase activity in Parksinsonian substantia nigra. J Neurochem 53: 692–697
Schapira AHV, Cooper M, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823–827
Sinha BK, Singh Y, Krishna G (1986) Formation of superoide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): reductive activation by NADPH cytochrome P 450 reductase. Biochem Biophys Res Commun 135: 583–588
Snyder SH, D'Amato RJ (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36: 350–358
Steventon G, Hunfrey C, Sturman S, Waring RH, Williams AC (1990) Monoamine oxidase B and Parkinson's disease. Lancet 335: 180
Sturman SG, Williams AC, Waring RH, Steventon GB (1991) Is monamine oxidase B metabolism of MPTP different in Parkinson's disease? Neurology 41 [Suppl 1]: 175 (Abstract)
Tanner CM (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 12: 49–54
Uitti RJ, Rajput AH, Rozdilsky B, Bickis M, Wollin T, Yuen WK (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological disease, and control brains. Can J Neurol Sci 16: 310–314
Williams A, Steventon G, Sturman S, Waring R (1991) Xenobiotic enzyme profiles and Parkinson's disease. Neurology 41 [Suppl 2]: 29–32
Yong VW, Perry TL (1986) Monoamine oxidase B, smoking and Parkinson's disease. J Neurol Sci 72: 265–272
Young WF, Laws ER, Sharbrough FW, Weinshilboum RM (1986) Human monoamine oxidase-lack of brain and platelet correlation. Arch Gen Psychiatry 43: 604–609
Zeller EA, Boshes B, Arbit J, Bieber M, Blonsky ER, Dolkart M, Hupiler SV (1976) Molecular biology of neurological and psychiatric disorders. I. Effects of Parkinsonism, age, sex, and L-Dopa on platelet monoamine oxidase. J Neural Transm 39: 63–77
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Checkoway, H., Costa, L.G., Woods, J.S. et al. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. J Neural Transm Gen Sect 4, 283–290 (1992). https://doi.org/10.1007/BF02260077
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260077